Lishou Pan1, Huilin Leng2, Yin Huang3, Ningyan Xia4, Lingjin Jin5, Han-Ting Zhang6. 1. School of Clinical Medicine, Yichun Vocational Technical College, 399 West Zhong Shan Road, Yichun, 336000, Jiangxi Province, People's Republic of China. 2. Department of Neurology, The People's Hospital of Yichun City, Yichun University, 1061 Jinxiu Road, Yichun, 336000, Jiangxi Province, People's Republic of China. lenghuilin999@163.com. 3. Department of Pharmacology, The People's Hospital of Yichun City, Yichun University, 1061 Jinxiu Road, Yichun, 336000, Jiangxi Province, People's Republic of China. 4. Department of Neurology, The People's Hospital of Yichun City, Yichun University, 1061 Jinxiu Road, Yichun, 336000, Jiangxi Province, People's Republic of China. 5. Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, People's Republic of China. 6. Departments of Neuroscience and Behavioral Medicine & Psychiatry, the Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, WV, 26506, USA.
Abstract
OBJECTIVE: To carry out a systematic review to help resolve the controversy of ischemic stroke (IS)/transient ischemic attack (TIA) in patients with primary immune thrombocytopenia (ITP). METHODS: A database search of PubMed and Ovid Embase was conducted for epidemiologic studies published up to December 17, 2019. The effective size was estimated by pooled prevalence, annualized incidence/risk, relative risk (RR), and their corresponding 95% confidence intervals (CIs). RESULTS: The systematic review included 14 eligible studies from 11 publications. The pooled annualized cumulative incidence was 0.15% (95% CI, 0.03-0.26%) per person-years. And the pooled annualized cumulative risk of IS/TIA of ITP was 0.86% (95% CI, 0.33-1.39%) per year based on 3 population-based cohort studies. There was a higher risk of incident IS/TIA in ITP patients than ITP-free subjects (pooled unadjusted or adjusted RR with 95% CI, 1.46 [1.22-1.74] or 1.50 [1.29-1.73]). CONCLUSIONS: IS/TIA was not uncommon in patients with primary ITP. ITP patients have a higher risk of IS/TIA compared with the reference cohorts. Healthcare professionals should take into account the risk of IS/TIA when treating ITP patients with or without a history of IS/TIA.
OBJECTIVE: To carry out a systematic review to help resolve the controversy of ischemic stroke (IS)/transient ischemic attack (TIA) in patients with primary immune thrombocytopenia (ITP). METHODS: A database search of PubMed and Ovid Embase was conducted for epidemiologic studies published up to December 17, 2019. The effective size was estimated by pooled prevalence, annualized incidence/risk, relative risk (RR), and their corresponding 95% confidence intervals (CIs). RESULTS: The systematic review included 14 eligible studies from 11 publications. The pooled annualized cumulative incidence was 0.15% (95% CI, 0.03-0.26%) per person-years. And the pooled annualized cumulative risk of IS/TIA of ITP was 0.86% (95% CI, 0.33-1.39%) per year based on 3 population-based cohort studies. There was a higher risk of incident IS/TIA in ITP patients than ITP-free subjects (pooled unadjusted or adjusted RR with 95% CI, 1.46 [1.22-1.74] or 1.50 [1.29-1.73]). CONCLUSIONS: IS/TIA was not uncommon in patients with primary ITP. ITP patients have a higher risk of IS/TIA compared with the reference cohorts. Healthcare professionals should take into account the risk of IS/TIA when treating ITP patients with or without a history of IS/TIA.
Authors: Ameet Sarpatwari; Dimitri Bennett; John W Logie; Amit Shukla; Kathleen J Beach; Adrian C Newland; Simon Sanderson; Drew Provan Journal: Haematologica Date: 2010-02-09 Impact factor: 9.941
Authors: Deirdra R Terrell; Laura A Beebe; Sara K Vesely; Barbara R Neas; Jodi B Segal; James N George Journal: Am J Hematol Date: 2010-03 Impact factor: 10.047